Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN10200 for prevention of episodic or chronic migraine in adults
2024-511101-28-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- Jul 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in episodic migraine and chronic migraine comparing IPN10200 with Placebo (2 arms). Primary endpoints: Adverse events incidence, Clinically significant laboratory changes and 7 more. Planned start Jul 2025; status: authorised.
02
Drugs
corabotase
03
Conditions
episodic migrainechronic migraine
Beyond the preview
Go deeper on 2024-511101-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511101-28-00.